<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113629</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1803</org_study_id>
    <nct_id>NCT04113629</nct_id>
  </id_info>
  <brief_title>Simplified Monitoring Myanmar SM2 Study</brief_title>
  <acronym>SM2</acronym>
  <official_title>Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-infected Patients in Myanmar (Simplified Monitoring Myanmar SM2 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Public Health, Yangon, Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the proportion of patients with undetectable HCV RNA at 12 weeks
      post-treatment (SVR12) following a course of DAA therapy delivered using a simplified
      schedule of safety and virological monitoring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 200 HIV/HCV co-infected patients who plan to commence DAA therapy at Specialist
      Hospital Waibargi and Mingaladon, will be enrolled by simple random sampling.

      In addition to standard of care medical procedures, each participant will complete a
      questionnaire and have blood taken for standard HCV RNA testing.

      They will also have a finger-stick capillary blood sample collected for a HCV point of care
      test, using the the Xpert HCV Assay performed in the GeneXpert point of care machine.

      Dried blood spot collection (DBS) for HCV core antigen and HCV RNA testing will be collected
      as a research sample. Concordance between standard of care method and new DBS method will be
      evaluated.

      The proportion of patients reaching SVR will be calculated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">January 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks post completion of commenced treatment</time_frame>
    <description>To evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12) following a course of DAA therapy delivered using a simplified schedule of safety and virological monitoring.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Liver Cirrhoses</condition>
  <condition>Liver Inflammation</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir/Daclatasvir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HCV point of care machine</intervention_name>
    <description>Xpert HCV Assay performed on the GeneXpert point of care machine</description>
    <arm_group_label>Sofosbuvir/Daclatasvir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to participate in this study.

          1. Have voluntarily signed the consent form.

          2. 18 years of age or older.

          3. HCV antibody positive.

          4. HIV antibody positive.

        Exclusion Criteria:

        Subjects who meet any of the exclusion criteria are not to be enrolled in this study.

          1. Clinically significant illness (other than HCV) or any other major medical disorder
             that may interfere with the subject treatment, assessment or compliance with the
             protocol.

          2. Creatinine clearance (CLcr) &lt; 30mL/min at screening.

          3. Pregnant or nursing female.

          4. Use of prohibited concomitant medications.

          5. Inability or unwillingness to provide informed consent or abide by the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PIp Marks, MPH</last_name>
    <phone>+61293850886</phone>
    <email>pmarks@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Kirby Institute, University of New South Wales Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail V Matthews, MbChB, PhD</last_name>
      <phone>+61 2 9385 0900</phone>
      <email>gmatthews@kirby.unsw.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Pip Marks</last_name>
      <phone>+61 2 9385 0886</phone>
      <email>pmarks@kirby.unsw.edu.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

